At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance
In Brief
A clinical study evaluating Tauroursodeoxycholic acid and Placebo tablet for HIV Related Insulin Resistance and 2 related conditions. Completed, enrolled 27 participants across 1 site.
Detailed Summary
Rates of cardiovascular disease and diabetes are more than 2-fold greater in HIV infected people than the general population. Protease inhibitor booster antiretroviral therapy (PI-ART) which is used by \~50% of HIV infected people in the USA is an established risk factor for diabetes. Tauroursodeoxycholic acid (TUDCA), a naturally occurring bile salt, improves insulin sensitivity in HIV uninfected subjects, although the mechanisms for these benefits are unclear. This study will explore the hypothesis that TUDCA will improve insulin action in people with HIV who are receiving PI-ART. Further, this project will clarify the molecular mechanisms responsible for these improvements potentially benefiting society, irrespective of HIV status.
Study Details
Timeline
Interventions
The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.